IDH1 and glioblastoma: Sandmann et al. in their retrospective analysis of the AVAglio (Avastin in Glioblastoma) Trial, found that only IDH1 wild-type GBM patients with proneural subtype derived both overall and progression-free survival benefit compared to placebo group [133].